1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 23,250 | 24,050 | 22:29 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BASTIDE obtains an extended license to operate in Canada in the Respiratory Care segment / Sale of French stomatherapy subsidiary CICA PLUS | 184 | Actusnews Wire | Caissargues, January 8, 2025 - Groupe Bastide, one of Europe's leading players in home healthcare services, announces its newly extended license to operate in the field of respiratory care in British... ► Artikel lesen | |
| 14.11.24 | BASTIDE: Highly dynamic organic growth in Q1 2024-25 at 9.0%: 10.9% growth in home healthcare services and rebound in the homecare business, up 6.0% / Disposal of Swiss commercial business finalized and 2024-2025 targets confirmed | 320 | Actusnews Wire | Caissargues, November 14, 2024 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2024-2025, ending September 30, 2024.
In... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 04.11.24 | BASTIDE: 2024-2025 financial calendar | 232 | Actusnews Wire | Caissargues, November 4, 2024
Events
Dates*
2024-2025 Q1 Revenue
Thursday November 14, 2024
2024-2025 H1 Revenue
Thursday February 13, 2025
2024-2025 H1 Results
Wednesday... ► Artikel lesen | |
| 23.10.24 | BASTIDE: 2023-2024 annual results: Solid growth in revenue and recurring operating margin of 8.5%, exceeding the target / improved profitability and a focus on reducing debt in 2024-25 | 234 | Actusnews Wire | Caissargues, October 23, 2024 - Groupe Bastide, leading European provider of home healthcare services, announces its earnings for the 2023-2024 financial year ended 30 June 2024. The full-year... ► Artikel lesen | |
| 29.08.24 | BASTIDE: Annual revenue: EUR 530 million (up 8.2%) exceeding the target of EUR 520 million / Organic growth accelerated in fourth quarter 2023-2024: up 9.5% / Profitability target of 8.4% confirmed for 2023-2024 | 277 | Actusnews Wire | Caissargues, August 29, 2024
In € millions
2022-2023 published
2022-2023* restated
2023-2024 published
Change
Fourth-quarter revenue
127.9
122.2
134.5
+10.1%
Annual... ► Artikel lesen | |
| 25.07.24 | BASTIDE: Financing resources reinforced through a new syndicated loan - Medium-term financing secured and debt maturity extended | 454 | Actusnews Wire | Caissargues, July 25, 2024
Groupe Bastide announced today that it has set up a new financing contract for €375 million, including a syndicated loan and a revolving credit facility, as part of its... ► Artikel lesen | |
| 15.05.24 | BASTIDE: Organic growth accelerated in third quarter 2023-2024 up 7.5% and sale of Homecare business in Switzerland in progress | 438 | Actusnews Wire | Caissargues, May 15, 2024
In € millions
2022-2023 published
2022-2023* restated
2023-2024 published
Change vs. restated
3rd quarter revenue
130.7
124.5
134.7
+8.2%
9-month... ► Artikel lesen | |
| 08.04.24 | BASTIDE: Respiratory care therapy: Bastide wins new United Kingdom region - EUR 10 million/year contract for a minimum of seven years | 292 | Actusnews Wire | Caissargues, April 8, 2024
Present in the United Kingdom home oxygen therapy market, since the acquisition of Baywater Healthcare in 2018, Bastide has announced that it has been appointed by... ► Artikel lesen | |
| 20.03.24 | BASTIDE: 2023-2024 half-yearly results: Organic growth up 5.7%, EBITDA up 7.5%, Increase in recurring operating profit despite the inflationary context and margin of 8.3%. 2023-2024 outlook confirmed | 398 | Actusnews Wire | Caissargues, March 20, 2024
In € millions - Year ended June 30
H1 2022-2023
H1 2023-2024
Change
Revenue
249.7
265.0
+6.1 %
EBITDA*
49.9
53.6
+7.5 %
EBITDA... ► Artikel lesen | |
| 15.02.24 | BASTIDE: Organic growth accelerated to 6.1% in second-quarter 2023-2024 and confirmation of 2023-2024 adjusted targets | 698 | Actusnews Wire | Caissargues, February 15, 2024
In €m
2022-2023
2023-2024
Organic growth
Published growth
Q1 revenue
119.5
127.9
+5.2%
+7.0%
Q2 revenue
129.9
137.1
+6.1%
+5.5%
H1... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ANSELL | 19,800 | -2,94 % | ANSELL LIMITED: Final Buyback Notice | ||
| AMBEA | 8,000 | 0,00 % | Ambea AB: Ambea's interim report July - September 2024 | Long-term quality management supports earnings improvements
CEO comments:
In the third quarter, Ambea continued to add more care places, and showed favourable organic growth and continued earnings... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 51,06 | -1,05 % | Siemens Healthineers: Sturm im Wasserglas | Die Meldung, dass der Siemens-Mutterkonzern darüber nachdenkt, seine Beteiligung am Medizintechnik-Unternehmen Siemens Healthineers zu reduzieren, machte die Aktie am letzten Handelstag des Jahres zum... ► Artikel lesen | |
| FRESENIUS | 35,070 | +1,59 % | EQS-News: Formycon AG: Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar zu Stelara® | EQS-News: Formycon AG
/ Schlagwort(e): Zulassungsgenehmigung
Formycon und Fresenius Kabi Canada erhalten Zulassung von Health Canada für FYB202/Otulfi® (Ustekinumab), ein Biosimilar... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 43,570 | +0,14 % | EQS-AFR: Fresenius Medical Care AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Fresenius Medical Care AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Fresenius Medical Care AG: Vorabbekanntmachung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 45,460 | -2,28 % | Carl Zeiss Meditec Aktie: Schwierige Balance im Fokus | Die Carl Zeiss Meditec AG verzeichnet am 4. Januar 2025 eine negative Kursentwicklung im XETRA-Handel. Der Medizintechnik-Konzern notiert aktuell bei 46,26 Euro, was einen deutlichen Rückgang im Tagesverlauf... ► Artikel lesen | |
| GERRESHEIMER | 68,80 | -0,22 % | WARBURG RESEARCH stuft GERRESHEIMER AG auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Das Analysehaus Warburg Research hat das Kursziel für Gerresheimer von 131 auf 113 Euro gesenkt und die Einstufung auf "Buy" belassen. Die jüngste Studie zum Novo-Nordisk-Mittel... ► Artikel lesen | |
| GENEDX | 96,78 | 0,00 % | GeneDX Slides on Asserting Industry Leadership Role | ||
| BRIGHTSPRING HEALTH SERVICES | 17,320 | -0,12 % | BrightSpring Health Services, Inc. Reports Third Quarter 2024 Financial Results and Increases Full Year 2024 Guidance | LOUISVILLE, Ky., Nov. 01, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based health services... ► Artikel lesen | |
| ECKERT & ZIEGLER | 49,200 | -0,24 % | Eckert & Ziegler Aktie: Vielversprechende Perspektiven in Sicht! | Die Eckert & Ziegler Aktie zeigt sich zu Jahresbeginn 2025 mit einem Kurs von 43,20 EUR weitgehend stabil. Der Berliner Spezialist für radioaktive Komponenten konnte im vergangenen Jahr eine positive... ► Artikel lesen | |
| NANO-X IMAGING | 8,755 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| PROGYNY | 18,230 | 0,00 % | Progyny, Inc. Announces Third Quarter 2024 Results | Sales Season Yields Over 80 New Clients, 1.1 Million New Covered LivesSelected by a Leading National Health Plan and a Regional Health Plan as Their Preferred Partner1.5 Million Lives Adopt Newest... ► Artikel lesen | |
| DRAEGERWERK | 49,000 | +2,73 % | Draegerwerk Aktie: Routinemäßige Entwicklungen | Die Drägerwerk-Aktie verzeichnete einen positiven Handelstag an der Frankfurter Börse, mit einem bemerkenswerten Kursanstieg von 2,0 Prozent auf 45,75 Euro. Im Tagesverlauf erreichte das Wertpapier... ► Artikel lesen | |
| INTUITIVE SURGICAL | 532,00 | +0,89 % | Intuitive Surgical Promotes Charlton, Samath, Loeb As EVPs | SUNNYVALE (dpa-AFX) - Intuitive Surgical, Inc. (ISRG), Friday announced three Executive Vice President promotions, effective immediately. The minimally invasive care and robotic surgery company... ► Artikel lesen | |
| UNITEDHEALTH | 511,10 | +0,55 % | Johnson&Johnson, UnitedHealth lead Thursday's market cap stock movers |
BASTIDE LE CONFORT MEDICAL SA gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell -0,42 % bei einem Aktienkurs von 23,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BASTIDE LE CONFORT MEDICAL SA finden Sie auf Wallstreet Online.
